ArticleFrontiers in pharmacology2026
Risk factors for Post-PCI cardiovascular events in coronary artery disease patients treated with clopidogrel combined with aspirin.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cytochrome P450 family two subfamily C member 19 (CYP2C19) loss-of-function (LOF) variants may influence clopidogrel response after percutaneous coronary intervention (PCI), but their prognostic relevance within combined clinical and procedural risk assessment remains incompletely defined. This study aimed to evaluate the association between CYP2C19 functional phenotype and major adverse cardiac and cerebrovascular events (MACCE) in coronary artery disease (CAD) patients receiving clopidogrel-based dual antiplatelet therapy (DAPT) after PCI. Method: This retrospective observational study included 280 consecutive CAD patients who underwent PCI with stent implantation and received aspirin plus clopidogrel. The primary endpoint was time to first MACCE. Multivariable Cox proportional hazards regression was the primary analysis, with logistic regression as a secondary supportive analysis. Kaplan-Meier analysis, subgroup interaction analyses, and sensitivity analyses were performed. Results: During a median follow-up of 32.0 months, 52 patients experienced MACCE (18.6%). In the primary Cox model, older age, diabetes mellitus, lower estimated glomerular filtration rate, lower left ventricular ejection fraction, greater total stent length, post-procedural Thrombolysis In Myocardial Infarction (MI) flow <3, and CYP2C19 LOF phenotype were associated with time to first MACCE. CYP2C19 LOF remained significant after adjustment (adjusted hazard ratio 1.74, 95% confidence interval 1.10-2.75; P = 0.018). Kaplan-Meier analysis showed lower MACCE-free survival in LOF carriers than in non-LOF patients (log-rank P = 0.007). Interaction analyses suggested stronger LOF-associated risk patterns in acute coronary syndrome and complex PCI subgroups. Conclusion: In clopidogrel-treated CAD patients after PCI, CYP2C19 LOF phenotype was associated with MACCE in a clinical-procedural risk framework. These findings support further prospective validation of integrated genotype-informed post-PCI risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.